Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report details a specific share repurchase transaction executed on November 1, 2011, authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,395.5 pence per share; lowest price paid was 1,364.5 pence per share.
- Treasury Holdings (Settled): 510,187,329 shares (9.16% of total issued share capital).
- Treasury Holdings (Including Unsettled): 512,739,248 shares (10.13% of current total voting rights).
- Shares in Issue: 5,062,170,915 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,200,000 shares on November 1, 2011. Consequently, the percentage of shares held in Treasury increased to 10.13% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (510,187,329 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,062,170,915 shares in issue) for disclosure threshold assessments under Financial Services Authority rules.
- Review the authorization limits from the May 5, 2011 Annual General Meeting to ensure the repurchase was within approved parameters.